Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: A real-world, retrospective, claims-based, comparative analysis

Experimental Hematology and Oncology

Volumn 3, Issue 1, 2014, Pages

  Smith, B D ^a   Beach, Charles L ^b   Mahmoud, Dalia ^c   Weber, Laura ^c   Henk, Henry J ^d  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Clinical Research and Development   (United States)

^c Global Pricing and Market Access   (United States)

^d Health Economics and Outcomes Research   (United States)

Author keywords

Acute myeloid leukemia; Azacitidine; Decitabine; Hospitalization; Managed care; Real world; Survival

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; BLEEDING; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; FEMALE; HOSPITALIZATION; HUMAN; INFECTION; INSURANCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL TIME;

EID: 84978022737     PISSN: None     EISSN: 21623619     Source Type: Journal    
DOI: 10.1186/2162-3619-3-10     Document Type: Article

References (18)

1. National Comprehensive Cancer Network (NCCN) NCCN guidelines version 2: acute myeloid leukemia. 2013, http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#aml, National Comprehensive Cancer Network (NCCN).
2. Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, Anderson JE, Petersdorf SH. Age and acute myeloid leukemia. Blood 2006, 107:3481-5. 10.1182/blood-2005-09-3724, 1895766, 16455952.
3. Juliusson G, Antunovic P, Derolf A, Lehmann S, Mollgard L, Stockelberg D, Anderson JE, Petersdorf SH. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009, 113:4179-87. 10.1182/blood-2008-07-172007, 19008455.
4. Behringer B, Pitako JA, Kunzmann R, Schmoor C, Behringer D, Mertelsmann R, Lubbert M. Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: a single-center retrospective study. Annals Hematol 2003, 82:381-9.
5. Hutchins LF, Unger JM, Crowley JJ, Coltman CA, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. New Eng J Med 1999, 341:2061-7. 10.1056/NEJM199912303412706, 10615079.
6. Surveillance Epidemiology and End Results (SEER) SEER stat fact sheets: acute myeloid leukemia 2012, Bethesda, MD: National Cancer Institute (NCI), Surveillance Epidemiology and End Results (SEER).
7. Deschler B, de Witte T, Mertelsmann R, Lubbert M. Treatment decision-making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica 2006, 91:1513-22.
8. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR, International Vidaza High-Risk MDS Survival Study Group Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009, 10:223-32. 10.1016/S1470-2045(09)70003-8, 19230772, International Vidaza High-Risk MDS Survival Study Group.
9. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U, Sanz G, List AF, Gore S, Seymour JF, Dombret H, Backstrom J, Zimmerman L, McKenzie D, Beach CL, Silverman LR. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010, 28:562-9. 10.1200/JCO.2009.23.8329, 20026804.
10. van der Helm LH, Scheepers ER, Veeger NJ, Daenen SM, Mulder AB, van den Berg E, Vellenga E, Huls G. Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients. J Hemat Oncol 2013, 6:29.
11. Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, Gau JP, Chou WC, Buckstein R, Cermak J, Kuo CY, Oriol A, Ravandi F, Faderl S, Delaunay J, Lysák D, Minden M, Arthur C. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 2012, 30:2670-7. 10.1200/JCO.2011.38.9429, 22689805.
12. Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010, 28:556-61. 10.1200/JCO.2009.23.9178, 20026803.
13. Lubbert M, Ruter BH, Claus R, Schmoor C, Schmid M, Germing U, Kuendgen A, Rethwisch V, Ganser A, Platzbecker U, Galm O, Brugger W, Heil G, Hackanson B, Deschler B, Dohner K, Hagemeijer A, Wijermans PW, Döhner H. A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica 2012, 97:393-401. 10.3324/haematol.2011.048231, 3291594, 22058219.
14. Quintas-Cardama A, Ravandi F, Liu-Dumlao T, Brandt M, Faderl S, Pierce S, Borthakur G, Garcia-Manero G, Cortes J, Kantarjian H. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood 2012, 120:4840-5. 10.1182/blood-2012-06-436055, 23071272.
15. Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL, Larson RA. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006, 24:3895-903. 10.1200/JCO.2005.05.4346, 16921040.
16. Passweg JR, Pabst T, Blum S, Bargetzi M, Li Q, Heim D, Stussi G, Gregor M, Leoncini L, Meyer-Monard S, Brauchli P, Chaladon Y. Azacytidine for acute myeloid leukemia in elderly or frail patients: a phase II trial (SAKK 30/07). Leukemia lymphoma 2014, 55:87-91. 10.3109/10428194.2013.790540, 23547838.
17. Maurillo L, Venditti A, Spagnoli A, Gaidano G, Ferrero D, Oliva E, Lunghi M, D'Arco AM, Levis A, Pastore D, Di Renzo N, Santagostino A, Pavone V, Buccisano F, Musto P. Azacitidine for the treatment of patients with acute myeloid leukemia: report of 82 patients enrolled in an Italian Compassionate Program. Cancer 2012, 118:1014-22. 10.1002/cncr.26354, 21761399.
18. Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi JC, Saunders LD, Beck CA, Feasby TE, Ghali WA. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. MedCare 2005, 43:1130-9.